Patents Represented by Attorney, Agent or Law Firm Amy Lesby
  • Patent number: 6692738
    Abstract: Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin™, interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: February 17, 2004
    Assignee: The General Hospital Corporation
    Inventors: David T. MacLaughlin, Joseph P. Vacanti, Patricia K. Donahoe, Peter T. Masiakos